Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CASP7 | P55210 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7975113 | 0.75 | PARP1 (0.46) | PARP1CYP1A2MEN1KMT2ACASP7 | |
| SCHEMBL23794347 | 0.74 | PPOX (0.41) | PARP1CYP1A2MEN1KMT2ACASP7 | |
| SCHEMBL29029657 | 0.72 | PARP1 (0.53) | PARP1CYP1A2MEN1KMT2ACASP7 | |
| SCHEMBL14463494 | 0.69 | CASP1 (0.61) | PARP1CYP1A2MEN1KMT2ACASP7 | |
| SCHEMBL28213228 | 0.69 | PARP1 (0.50) | PARP1CYP1A2MEN1KMT2ACASP7 | |
| SCHEMBL28257878 | 0.68 | KMT2A (0.67) | PARP1CYP1A2MEN1KMT2ACASP7 | |
| SCHEMBL5746359 | 0.66 | MEN1 (0.65) | PARP1CYP1A2MEN1KMT2ACASP7 | |
| SCHEMBL29610334 | 0.66 | PARP1 (0.46) | PARP1CYP1A2MEN1KMT2ACASP7 | |
| SCHEMBL8637610 | 0.66 | MEN1 (0.59) | PARP1CYP1A2MEN1KMT2ACASP7 | |
| SCHEMBL11594529 | 0.66 | HKDC1 (0.63) | PARP1CYP1A2MEN1KMT2ACASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016028225-A1 | PLATINUM COMPLEXES AS ANTICANCER AGENTS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-02-25 | — | — | WO | disclosed |
| WO-2007064345-A9 | HETEROCYCLIC-SUBSTITUTED BIS-1,8 NAPHTHALIMIDE COMPOUNDS, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE | GENENTECH INC (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070134243-A1 | Antibody drug conjugates and methods | BOD1L1, MKI67, CCNI | PARP1 113/4885CYP1A2 2187/4885MEN1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.